Phenoxypropazine

Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.^{[1][2][3][4][5]}

Phenoxypropazine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (1-methyl-2-phenoxy-ethyl)hydrazine
CAS Number	3818-37-9
PubChem CID	71467
ChemSpider	64548
UNII	8E92V52324
ChEMBL	ChEMBL1909286
CompTox Dashboard (EPA)	DTXSID1048837
Chemical and physical data
Formula	C9H14N2O
Molar mass	166.224 g·mol−1

See also

• Hydrazine (antidepressant)